Clinical trial · Observational
Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female
Trajectory Analysis of Symptom Distress and Cancer-related Fatigue After Adjuvant Chemotherapy in Breast Cancer Female: an Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
When receiving adjuvant chemotherapy, a variety of symptoms will appear and it is very painful. These symptoms occur at the same time and are related to each other. The symptom distress may affect the patient's compliance with adjuvant chemotherapy and whether the adjuvant chemotherapy can be completed on schedule. Among the symptoms of trouble, cancer-related fatigue is the most common, and the incidence can be as high as 99%. In this study, I want to track the population of breast cancer patients receiving adjuvant chemotherapy, and women in the control group who receive only anti-hormonal breast cancer or carcinoma in situ. During the treatment period, at different time points, it also collects subjective symptom distress changes and changes. The study aimed cancer-related exhaustion is measured to gain a deeper understanding of the effects of symptom troubles suffered by patients during treatment. We also hoped that in the future, it can be provided to colleagues in clinical work and can be given to breast cancer patients receiving adjuvant chemotherapy and increased holistic care quality.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Symptom Distress During Breast Cancer Treatment | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| breast adenocarcinoma receiving chemotherapy | Behavioral | — | UNRESOLVED |
| Control-for | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- breast adenocarcinoma
- description
- 1. The surgical pathological tissue report confirms the diagnosis of breast adenocarcinoma women with stage I\~III 2. Those who are admitted to the hospital and receive adjuvant chemotherapy for the first time. 3. Age (inclusive) over 20 years old.
- interventionNames
- Behavioral: breast adenocarcinoma receiving chemotherapy
- label
- Control
- description
- 1. The surgical pathological tissue report establishes women diagnosed as stage 0 to stage III breast cancer 2. Those who are admitted to the hospital to receive anti-hormonal drug treatment. 3. Age (inclusive) over 20 years old.
- interventionNames
- Behavioral: Control-for
Primary outcomes (6)
- measure
- Trajectory of Symptom distress
- timeFrame
- T0 to T6, T0 pre chemotherapy; T1, chemotherapy 1 month; T2, chemotherapy 2 month; T3, chemotherapy 3 month;T4, chemotherapy 4 month;T5, chemotherapy 5 month;T6, chemotherapy 6 month;
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: 1. The surgical pathological tissue report confirms that the diagnosis is zero stage breast carcinoma in situ women and stage I\~III Breast cancer women. 2. Those who are admitted to the hospital for the first time adjuvant chemotherapy or hormonal therapy. 3. Age (inclusive) over 20 years old Exclusion Criteria: 1. Women with breast cancer who are unconscious or unable to express.
References
Publications (0)
Data not yet available